Company Description
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.
Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form.
It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021.
SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Itschak Shrem |
Contact Details
Address: 20 Raul Wallenberg Street, Tower A Tel Aviv, L3 6971916 Israel | |
| Phone | 972-3-6103100 |
| Website | scisparc.com |
Stock Details
| Ticker Symbol | SPRC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001611746 |
| CUSIP Number | M82618105 |
| ISIN Number | IL0010951403 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Oz Adler CPA | Chief Executive Officer and Chief Financial Officer |
| Itschak Shrem | President and Director |
| Dr. Adi Zuloff-Shani Ph.D. | Chief Technologies Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | EFFECT | Notice of Effectiveness |
| Jun 17, 2024 | POS AM | Post-Effective amendments for registration statement |
| Jun 14, 2024 | 6-K | Report of foreign issuer |
| Jun 3, 2024 | 6-K | Report of foreign issuer |
| May 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| May 2, 2024 | 425 | Filing |
| May 2, 2024 | 6-K | Report of foreign issuer |
| May 2, 2024 | 20-F/A | Filing |
| Apr 12, 2024 | 425 | Filing |
| Apr 11, 2024 | 6-K | Report of foreign issuer |